Major depressive disorder (MDD) continues to be a prevalent disease worldwide. While selective serotonin reuptake inhibitors and other medications continue to be prescribed, further research has been conducted toward other treatment modalities. Within the past decade, ketamine, an N-methyl-d-aspartate receptor antagonist, has been extensively studied as a new treatment for MDD. Recent studies...
Major depressive disorder (MDD) is a prevalent and highly debilitating illness that causes significant functional impairment in many patients. Conventional pharmacotherapy, such as monoaminergic antidepressant agents, usually takes several weeks to improve symptomatology and has some adverse side effects, and in many cases, patients show clinical non-response. This has resulted in a quest to...
Cannabis sativa contains phytocannabinoids that are psychoactive and neurotoxic (delta-9-tetrahydrocannabinol: Δ9THC) or nonpsychoactive and presumptively neuroprotective (cannabidiol: CBD). Along with rising legalization, availability, and demand, the Δ9THC:CBD ratio also has increased. Cannabis legalization means that use will likely increase in pregnant or breastfeeding women, affecting all...